<Anchor>



It is expected that a treatment for coronavirus in the United States will be approved within this month.



At the same time, an injection of an antibody treatment placed into the muscle has been developed, and medical reporter Cho Dong-chan will explain in detail how effective it is for Corona.



<Reporter>



Merck, a US pharmaceutical company, has applied to the FDA and the US Food and Drug Administration for emergency use of a corona treatment that is taken twice a day for 5 days.



It is said to reduce the chance of hospitalization or death by 50% when taken.



[Anthony Fauci/National Institute of Health: The US Food and Drug Administration will review the data and look at the effect in the shortest possible time and then approve it.]



It is scheduled to produce 10 million servings within

this

year, but purchase requests from around the world are flooding in.



[Grag Hunt/Australian Health Minister: Taking a corona treatment will help cure it much easier.]



AstraZeneca was the first to develop an antibody treatment injection that is placed into the muscle.



It has been shown to reduce the risk of hospitalization and death by 50%.



Merck's Molnupiravir, Roche, and Pfizer's oral tablet and intravenous drug remdesivir all stop the virus from multiplying in cells.



However, antibody treatment blocks the virus from entering the body.



In particular, AstraZeneca claims that the treatment of severe patients is also effective. The treatments that have been released so far have been mainly used for mild patients and have prevented them from getting worse.



The rate from mild to severe, 1.6 out of 10, would be used for all 10 people if the drug was cheap.



However, the price of one serving of molnupiravir, an oral treatment, is 900,000 won, which is burdensome.



Ultimately, the task remains to decide which patients to use and when.



Merck said it would allow generic drugs after a period of time, while Roche said it would make little profit.



Follow-up information must be tracked and understood to strategically purchase treatment.



(Video editing: Park Ji-in, VJ: Oh Se-gwan, CG: Jang Seong-beom)